Table 1.
Clinical features of the patients and T-cell receptor (TCR) status.
| Case | Age | Sex | Celiac Disease | Location | Treatment | Prognosis (Survival Time) |
TCR |
|---|---|---|---|---|---|---|---|
| 1 | 66 | Female | No | Small and Large intestine | Operation | Unknown | γδ |
| 2 | 64 | Male | No | Small intestine | Operation, DeVIC | Dead (Unknown) |
γδ |
| 3 | 58 | Male | No | Small intestine | Operation | (Unknown) | γδ |
| 4 | 74 | Female | No | Small intestine | Operation, CHOP | Unknown | γδ |
| 5 | 49 | Female | No | Small intestine | Operation, CHO, GEM | Dead (6 months) |
γδ |
| 6 | 70 | Female | No | Small intestine | Operation | Alive (4 months) |
γδ |
| 7 | 62 | Female | No | Small intestine | Operation, CHOP | Dead (7 months) |
γδ |
| 8 | 61 | Female | No | Large intestine | Operation, DeVIC | Alive (50 months) |
γδ |
| 9 | 81 | Female | No | Small intestine | Operation, THP-COP, CDE-11 | Dead (8 months) |
αβ |
| 10 | 64 | Female | No | Small intestine | Operation, EPOCH | Unknown | γδ |
| 11 | 75 | Male | No | Small intestine | Operation, CHO | Dead (3 months) |
αβ |
The data of TCR are from reference [18]. Abbreviations: DeVIC (carboplatin, ifosfamide, etoposide, and dexamethasone); CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone); CHO (cyclophosphamide, doxorubicin, and vincristine); GEM (gemcitabine); THP-COP (cyclophosphamide, pirarubicin, vincristine, and prednisolone); CDE-11 (irinotecan, carboplatin, etoposide, and dexamethasone); EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisolone).